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Abstract
Down syndrome (DS) is caused by three copies of human chromosome 21 (Hsa21) and results in 
phenotypes including intellectual disability and skeletal deficits. Ts65Dn mice have three copies of 
~50% of the genes homologous to Hsa21 and display phenotypes associated with DS, including 
cognitive deficits and skeletal abnormalities. DYRK1A is found in three copies in humans with 
Trisomy 21 and in Ts65Dn mice, and is involved in a number of critical pathways including 
neurological development and osteoclastogenesis. Epigallocatechin-3-gallate (EGCG), the main 
polyphenol in green tea, inhibits Dyrk1a activity. We have previously shown that EGCG treatment 
(~10mg/kg/day) improves skeletal abnormalities in Ts65Dn mice, yet the same dose, as well as 
~20mg/kg/day did not rescue deficits in the Morris water maze spatial learning task (MWM), 
novel object recognition (NOR) or balance beam task (BB). In contrast, a recent study reported 
that an EGCG-containing supplement with a dose of 2–3 mg per day (~40–60mg/kg/day) 
improved hippocampal-dependent task deficits in Ts65Dn mice. The current study investigated if 
an EGCG dosage similar to that study would yield similar improvements in either cognitive or 
skeletal deficits. Ts65Dn mice and euploid littermates were given EGCG [0.4 mg/mL] or a water 
control, with treatments yielding average daily intakes of ~50 mg/kg/day EGCG, and tested on the 
multivariate concentric square field (MCSF)—which assesses activity, exploratory behavior, risk 
assessment, risk taking, and shelter seeking—and NOR, BB, and MWM. EGCG treatment failed 
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to improve cognitive deficits; EGCG also produced several detrimental effects on skeleton in both 
genotypes. In a refined HPLC-based assay, its first application in Ts65Dn mice, EGCG treatment 
significantly reduced kinase activity in femora but not in the cerebral cortex, cerebellum, or 
hippocampus. Counter to expectation, 9-week-old Ts65Dn mice exhibited a decrease in Dyrk1a 
protein levels in Western blot analysis in the cerebellum. The lack of beneficial therapeutic 
behavioral effects and potentially detrimental skeletal effects of EGCG found in Ts65Dn mice 
emphasize the importance of identifying dosages of EGCG that reliably improve DS phenotypes 
and linking those effects to actions of EGCG (or EGCG-containing supplements) in specific 
targets in brain and bone.
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1. Introduction
Down syndrome (DS), the leading genetic cause of intellectual disability, is caused by the 
three copies of human chromosome 21 (Hsa21) [1, 2]. DS has an incidence of ~1 in 700 live 
births and results in phenotypes that affect the central nervous and skeletal systems in all 
humans with DS [3–5]. Cognitive and neurodevelopmental disabilities are characterized by 
deficiencies in hippocampal-dependent memoryfunctions, reduced sizeof hippocampus and 
cerebellum, reduced dendritic and axonal number and volume, early occurrence of 
Alzheimer disease, motor dysfunction and altered hippocampal synaptic plasticity [6–9]. 
Humans with DS also exhibit skeletal structures that are generally smaller than normal and 
with reduced bone mineral density (BMD) that can lead to osteoporosis. [10–12].
Mouse models have been used to study the complex genotype-phenotype relationship 
associated with DS, assessing both the role of a chromosomal region or specific genes on the 
pathogenesis of DS and possible therapeutic interventions [13–16]. The Ts(1716)65Dn 
(Ts65Dn) mouse model is the most extensively studied and widely used animal model of DS 
and captures several behavioral and skeletal defects that are seen in humans with DS [13, 
17–20]. We and others have shown that Ts65Dn mice exhibit behavioral and functional 
neurological deficits, including a variety of deficits on learning and memory tasks [20, 21]. 
Ts65Dn mice show deficits in novel object recognition (NOR) and spontaneous alternation 
[6], show increased locomotor activity [22, 23], have deficits in the Morris water maze 
(MWM) place learning (using the hidden platform version) and (under some testing 
conditions) on the cued task of the visible platform version [20, 23, 24], have gait 
abnormalities [25] and motor coordination deficits [23]. For skeletal parameters in DS 
mouse models, we and others have identified significant deficits in BMD, trabecular bone 
parameters (thickness, separation and number) and cortical bone measures in Ts65Dn mice 
compared to euploid control mice [17]. Significant deficits in mineral apposition rate 
(MAR), bone formation rate (BFR), and strength properties in trisomic mice compared to 
controls were also observed [17, 26, 27].
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The gene for Dual-specificity tyrosine phosphorylation-regulated kinase 1a (DYRK1A) is 
found in three copies in humans with DS [28] and is thought to play a key role during CNS 
development and osteoclastogenesis. Notably, adverse effects may be present both with 
increased and decreased DYRK1A expression levels [29–31]. Dyrk1a protein levels were 
found to be ~1.5 fold higher than euploid control levels in the cortex, cerebellum and 
hippocampus of 5–6 month old Ts65Dn mice [32] and in brain of 7–8 month old Ts65Dn 
mice [33]. However, other studies have reported no differences in brain homogenate Dyrk1a 
mRNA levels in 5-month-old Ts65Dn mice [34]. In post-mortem cases of individuals with 
DS (age groups of 10–30 years and 40+ years old), Western blot analysis found that 
DYRK1A protein levels were increased 1.5 fold above age-matched controls in the frontal, 
temporal, occipital, and cerebellar cortices and in cerebral and cerebellar white matter; 
however, brains from infants (1–3 years old) in this study did not have significantly 
increased DYRK1A protein expression [33]. These studies support the growing possibility 
that Dyrk1a overexpression is both spatially and temporally regulated during development in 
DS. Furthermore, only a few studies have reported levels of Dyrk1a kinase activity; 15-
month-old Ts65Dn mice exhibited increased Dyrk1a kinase activity in brain tissue as 
compared to controls [35], whereas another study reported no differences in Dyrk1a kinase 
activity in cerebellum hippocampus and cerebral cortex between 6 week old Ts65Dn and 
control mice [23]. Understanding functional Dyrk1a kinase activity differences between 
Ts65Dn and control mice at specific developmental periods in specific tissues is a necessary 
component for assessing the efficacy of pharmacotherapies targeting Dyrk1a.
Epigallocatechin-3-gallate (EGCG) is the most prevalent polyphenol found in green tea [36] 
and has been tested for therapeutic effects in various pathologies, including anti-cancer 
activity, anti-oxidant activity, anti-bacterial activity, anti-allergic activity and anti-
inflammatory activities [37–41]. EGCG is a small molecular inhibitor of DYRK1A activity 
and is thought to function by binding to the ATP binding domain of the protein thereby 
inhibiting its kinase activity [42, 43]. EGCG, either alone or in supplements containing 
EGCG, has been tested as a potential therapy in mouse models of DS [23, 26, 44–48] and in 
humans with DS [45, 49, 50]. In one recent study [45] trisomic mice were given an EGCG-
containing supplement (Life Extension® Mega Green Tea Extract, Lightly Caffeinated) in 
drinking water that was reported to deliver 2–3 mg of EGCG per day per mouse (i.e., a daily 
dosage of ~80–120 mg/kg [for a 25 g mouse] that would yield a final effective dosage of 
~40–60 mg/kg per day after accounting for the known degradation of EGCG [23, 44]). This 
dosage rescued acquisition of spatial navigation and normalized thigmotaxic behavior in the 
MWM, and improved novel object recognition (NOR) discrimination ratios [45]. Those 
findings stand in contrast with studies in our laboratory that used either a three-week or a 
seven-week treatment of pure EGCG (concentration of 0.124 mg/mL) beginning in early 
adolescence that delivered a dosage of either ~10 mg/kg/day (EGCG in water) or ~20 
mg/kg/day (stabilized EGCG in acidified water and corrected for degradation). The 10 
mg/kg/day dosage improved skeletal deficits including femoral BMD, percent trabecular 
bone volume, trabecular number and trabecular thickness in Ts65Dn mice [26], but neither 
the 10 nor the 20 mg/kg/day dosage improved performance in the MWM, NOR, or balance 
beam motor coordination task [23].
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The goal of the current study was to test whether the lack of EGCG effects in our previous 
study [23], compared to the improved phenotypes with the EGCG-containing supplement 
found by De la Torre and colleagues [45], may have been be due to the lower dosages of 
EGCG. The current study administered a dosage of pure EGCG intended to approximate the 
EGCG dosage that we determined was delivered in the De la Torre et al. [45] study (~50 
mg/kg/day), which includes our correction for the ~50% degradation of EGCG that is known 
to occur when EGCG is dissolved in the drinking water [23, 44]. Thus, Ts65Dn mice were 
administered either EGCG [0.4mg/mL, stabilized in acidified water], which yielded a target 
average daily intake of ~50 mg/kg/day after correction for known degradation, or acidified 
water alone. Given that the current study used a higher concentration of EGCG (0.4 mg/mL) 
for a longer duration (7 weeks) than our previous study (0.124 mg/mL for 3 weeks) that 
showed that EGCG improved bone phenotypes [26], an additional goal was to determine 
whether this higher dosage for longer duration would yield more extensive improvement in 
skeletal deficits than previously observed. The current study was also the first to employ the 
Multivariate Concentric Square Field (MCSF) in mouse models of DS, a behavioral task 
originally developed by Meyerson and colleagues that assesses patterns of activity and 
exploration in a complex novel environment, and has been shown to identify distinct 
behavioral phenotypes in rodent models, quantify locomotor activity, exploratory behavior, 
risk-taking, risk assessment, and shelter seeking, [51]. MCSF appears to be well suited to 
study behavioral phenotypes associated with neurodevelopment disorders given prior results 
from various rat and mouse models indicating its sensitivity to effects of traumatic brain 
injury [52], early life maternal separation stress [53], and disparities in lines of rodents 
selectively bred for differences in voluntary alcohol drinking [54]. Another key goal of this 
study was to determine Dyrk1a protein levels using Western blot analysis and to quantify 
kinase activity using a modified HPLC-based assay that has been suggested to measure 
Dyrk1a-related activity [55]. To our knowledge, this is the first report of quantification of 
Dyrk1a levels and kinase activity in specific brain regions and bone assessing whether 
EGCG treatment altered Dyrk1a protein and activity in a manner that was linked with 
changes in behavioral and skeletal DS-related phenotypes.
2. Materials and Methods
2.1 Animals
All animals were housed in the secure AAALAC-accredited Science Animal Resource 
Center facility in the IUPUI School of Science. Ts65Dn females (approximately 50% B6 
and 50% C3H background with small trisomic marker chromosome) were bred to B6C3F1 
males (both obtained from the Jackson Laboratory [Bar Harbor, ME]) in rooms with a 
standard 12:12 light:dark cycle to generate the mice used in the study. Only male mice were 
used due to the subfertile nature of Ts65Dn mice, making it necessary to retain Ts65Dn 
females as breeders for colony maintenance. On postnatal day (PD) 21, the male mice were 
weaned and single-housed in standard mouse cages, and randomly assigned to the different 
treatment groups. The vivarium containing the mice undergoing treatment was maintained 
on a reverse 12:12 light:dark cycle with white light off between 0800–2000, during which 
time only red light was present. Experiments with animals were carried out in accordance 
Stringer et al. Page 4
Physiol Behav. Author manuscript; available in PMC 2018 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
with the NIH Guide for the Care and Use of Laboratory Animals and received prior approval 
from the IACUC committee at IUPUI (SC213R and SC255R).
2.2 EGCG/Water Treatment
EGCG (>95% purity, as determined by LC/MS analyses [44]) was prepared by making a 
stock solution of 15 mg/mL EGCG in phosphate buffered saline (PBS). Treatments were 
delivered via the drinking water in a concentration of 0.4 mg/mL EGCG, prepared by 
diluting the stock solution in tap water, and pH balanced (5–5.5) by slowing adding 
phosphoric acid (approximately 100μL/100mL tap water). Treatments started on PD 24, 
usually 3 days after weaning. Treatments (EGCG or acidified water control) were placed in 
drinking tubes and the mice were allowed access ad libitum to its designated treatment as its 
sole source of fluid. The volumes consumed and animal weights were recorded every 48 
hours at the time the treatments were changed. Treatments continued throughout the 
duration of behavioral testing, which ended on PD 68.
2.3 Behavioral Timeline
Figure 1 shows the behavioral timeline for the study. Starting on PD 43, mice were handled 
by the experimenter in the vivarium for two consecutive days. Behavioral testing began with 
the MCSF test on PD 45-PD 46, followed by three consecutive days of NOR (PD 47-PD 
49). After two days of rest, the mice were trained for three consecutive days on the balance 
beam task (PD 52-PD 54), followed by the MWM task from PD 57-PD 64. A final NOR 
task was administered on PD 65-PD 67. The NOR and MWM tasks were all conducted 
using previously published protocols [23]. On PD 68, mice were euthanized using isoflurane 
followed by cervical dislocation. Tissue from the cerebellum, cerebral cortex and 
hippocampus was rapidly dissected, snap frozen, and stored at −80°C. The mouse carcass 
was stored at 4°C, and in the following week, femurs were dissected, wrapped in PBS-
soaked gauze and frozen at −20°C until analysis was performed.
2.3.1 Multivariate Concentric Square Field (MCSF)—Mice were tested in the MCSF 
on PD 45 and 46. The MCSF apparatus, adapted from Ekmark-Lewén [52], is a complex, 
multi-compartment novel environment in which animals may move around and explore 
freely among various compartments and areas, including ones that are open, elevated, or 
sheltered [see Supplemental Figure 1 for image]. The MCSF design consists of an outer 
square field [70 cm × 70 cm × 26 cm (high)] that encloses a smaller interior center square 
field [41 cm × 41 cm × 25 cm (high)] centered within the larger field. The center square field 
contains a demarcated circular zone [center circle: 16 cm diameter] to record activity in the 
center of the MCSF. Three of the sides of the center square contain circular openings (8 cm) 
that permit entry into one of three corridors that make up three sides of the perimeter of the 
MCSF: the north corridor (containing an entrance to the slope and bridge), the south corridor 
(containing an entrance to the dark corner room (DCR), and the west corridor (open sloped 
incline to the hurdle that contains two, 2.5-cm holes with photocells underneath the holes to 
measure nose pokes). The fourth side of the MCSF perimeter is side-illuminated by a 
fluorescent light (approximately 320 lux) and contains an elevated bridge constructed of 
stainless steel (10 mm) wire-mesh that is elevated 177 cm above the floor and is accessible 
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from the north corridor. The DCR is enclosed and covered, and can only be accessed 
through the south corridor.
For each session, the animal was placed in the center zone facing the wall with no openings; 
and its activity was video recorded for each 20-minute session in dim light (15–20 lux) in all 
areas except for the dark corner room (1–2 lux) and the lighted bridge area (320 lux). The 
MCSF was thoroughly cleaned between testing sessions with 70% ethanol. Photocell counts 
and fecal boli were recorded after each 20-minute session by the experimenter.
All sessions were scored by three independent observers blind to experimental treatment and 
genotype. Behavioral measures were obtained using The Observer XT Version 8 software 
(Noldus Information Technology, Wageningen, The Netherlands), and included measures of 
frequency of entries, duration, duration per visit, and latency to initial visit for each defined 
location within the MCSF. Measurements of rearing were not available due to unreliable 
identification of defined rearing events in video playback. The three scorers’ results were 
averaged to obtain the score value that was used for each animal. The correlation of scores 
across all measures across the three raters was r >+0.99. The full listing of all behavioral 
measures obtained from the scoring is provided Table 1.
Meyerson and colleagues have developed rank-order analytic approaches to data from the 
MCSF that identify categories of behavioral phenotypes, using the sums of ranks of 
designated measures that were combined to form identified categories of behavioral 
activities in the MCSF. These combined measures (that they refer to as “trend analysis”) 
reflect common underlying functions expressed in different behaviors or in different 
behavioral strategies across the complex environment of the MCSF, classified as general 
activity; exploratory behavior, risk assessment, risk taking and shelter seeking [56]. The 
value of the MCSF with its ethological behavioral dimensions was demonstrated in that 
study by showing that the behavioral trends extracted from the MCSF were more sensitive to 
anxiolytic effects of diazepam than the standard measure of the elevated plus maze. We used 
similar subsets of measures modified from those of Meyerson [56], defining the five 
behavioral categories in the following way (see Table 1): “Total entries”—a measure of 
locomotor activity—included the frequency of entries into the hurdle, DCR, slope, bridge, 
center circle and center square, along with the summed frequency of entries into the three 
corridors (TotCorr). ”Exploratory behavior” included the total duration of time spent in the 
hurdle, the duration per visit to the hurdle, total photocell counts, latency to initial slope 
visit, latency to initial hurdle visit, and the duration per visit to the center square. ”Risk 
assessment” included the latency to leave the center square, the duration per visit to the 
slope, as well as the difference between latency to initial bridge visit minus the latency to 
initial slope visit. “Risk-taking” included the total duration of bridge visits, duration per visit 
to the bridge, the total duration of center circle visits, and duration per visit to the center 
circle. “Shelter seeking” included the frequency of DCR entries, the total duration of DCR 
visits, the duration per visit to the DCR, and the latency to initial visit to the DCR.
2.3.2 Novel Object Recognition (NOR)—The NOR task was performed over three 
consecutive days. For the first day, animals underwent habituation, in which they were 
placed individually inside the painted plywood test box and allowed to explore the 
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environment for 15 minutes. On the next day (object exposure day), two matching objects 
(8.5–11.0 cm tall; 3.0–4.5 cm base) were placed near the NW and SE corners of the box, 
approximately 5 cm from the wall, and each mouse was placed in the middle of the arena 
and allowed 15 minutes to explore the arena and objects. On the final day (test day) one 
object from the previous day and one novel object were placed inside and the mice were 
given 15 minutes to explore. Activity on each day was recorded with video tracking using 
ANYMAZE software (Stoelting Co, Wooddale, IL). The discrimination ratios of the time 
exploring each object on the test day were determined using the following formula: 
discrimination ratio (%) = [(time exploring novel object- time exploring familiar object) / 
total exploration time for both objects] * 100.
2.3.3 Balance Beam Task—The balance beam task was performed over three 
consecutive days. The apparatus consisted of 1 m painted wooden beams with a surface 
width of either 19 mm, 12 mm, 9 mm or 6 mm, situated 58 cm above the floor. A black goal 
box was located at the end of the beam, and contained bedding from the animals’ cage. On 
the first day, a cohort of mice (2–5 mice) was brought into the testing room each mouse was 
trained to walk from one side of the 19mm-wide beam to a black goal box, starting at 
varying distances from the box. On the second day, the mice were trained to cross the entire 
length of the 12 mm-wide beam without stopping on three consecutive trials. On the third 
day, the mice were tested on three trials each on the 12 mm-, 9 mm- and 6 mm- wide beams. 
A Logitech camera at the opposite end of the goal box recorded these trials. The video 
records of the test day were scored by three trained independent scorers, blind to genotype 
or treatment, to quantify the number of hind paw slips, defined as either the left or right hind 
paw entirely missing the beam.
2.3.4 Morris Water Maze Place Learning Task (MWM)—The Morris water maze 
(MWM) utilized a 125 cm (diameter) white tank filled to within 25 cm of the rim with water 
(24–26°C) clouded with white tempera paint. Training consisted of 7 days of acquisition, 
followed by a single probe trial given 24 hours after the last training day. The acquisition 
training consisted of four trials a day, at random starting positions for each trial. In each trial, 
the animal was allowed to swim for 60 seconds or until it located and climbed onto the 
platform. If the platform was not found in the 60 seconds, the experimenter gently moved 
the mouse to the platform. For acquisition trials, video tracking and data collection software 
(HVS Image, Mountain View, CA, USA) was used to obtain measures of latency to find the 
platform path length (cm), time spent within 25.4 cm of the wall (thigmotaxis), time spent 
not moving (floating), and swimming speed (cm/sec). Mice were tested in cohorts of three to 
four, with an inter-trial interval of approximately 3–4 minutes. Twenty-four hours after the 
last training day, the mice were given a 60-sec “probe trial” in which the platform was 
removed and the animal’s search path was recorded and scored for spatial biases using four 
superimposed virtual counting discs (27 cm diameter) in the center of each quadrant (over 
the four possible platform positions used for training). Probe trial measures included time 
spent in, latency to enter, and numbers of crossings through each of the four virtual counting 
discs. These measures were used to quantify the spatial distribution of the search strategy of 
each animal by a priori comparisons of the time spent in the target location (trained during 
acquisition) to the mean time spent in the three non-target locations.
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2.4 Micro Computed Tomography (μCT)
The left femora were thawed to room temperature and then scanned using a high-resolution 
μCT system (SkyScan 1172, Bruker microCT, Belgium). Daily calibrations were performed 
prior to scanning the bones using two cylindrical hydroxyapatite phantoms (0.25 and 0.75 
g/cm3 calcium hydroxyapatite). The distal and midshaft portion of the femur were scanned 
using the following parameters: voltage 60 kV, resolution 6 μm, binning mode 2 k and filter 
Al 0.5 m. Scans were reconstructed using NRecon and CTan software (SkyScan, Bruker 
microCT, Belgium). After scanning, bones were wrapped in PBS-soaked gauze and stored at 
−20°C until mechanical testing. Bone mineral density (BMD) was calculated using the 
hydroxyapatite phantoms as a standard. The trabecular, and cortical analysis was performed 
using a previously published protocol [57]. For cortical bone analysis, a standard site was 
chosen at 60% of the bone’s total length away from the distal growth plate. Seven transverse 
slices were generated from the above site and cortical properties were obtained using a 
custom Matlab code (MathWorks, Inc. Natick, MA). The regions of interest for femora were 
kept constant across genotype and treatment groups. Trabecular analysis was performed on 
the distal metaphysis with a region of interest defined as 10% of total bone length, starting at 
the proximal end of the distal growth plate then extending proximally. The region of interest 
was auto-segmented to only include trabecular bone using a custom Matlab code [57]. Two 
bones were excluded from the cortical analysis because of extreme non-normality.
2.5 Mechanical Testing
Following μCT, the mechanical properties of the femur were determined in 3-point bending 
(ElectroForce 3200; Eden Prairie, MN USA). The left femora were thawed to room 
temperature, and tested in the AP direction (anterior surface in tension). The loading 
spanwas set at 6 mm and a preload of 0.5 N was applied to the midpoint of the bone to 
establish contact. Once preloaded, the bone was monotonically tested to failure at a 
displacement rate of 0.025 mm/sec. Mechanical data from five bones were not obtained due 
to technical errors and therefore were excluded from the analysis (1 Eu+Water, 1 Eu+EGCG, 
1 Ts+Water, 2 Ts+EGCG).
2.6 High Performance Liquid Chromatography (HPLC) Kinase Activity Assay
Protein was isolated from frozen (snap frozen then stored at −80°C) hippocampus, 
cerebellum, cerebral cortex, and femurs utilizing a protocol adapted from previous studies 
[58, 59]. The isolated protein was quantified using the Bradford assay to determine the 
concentration before proceeding with a HPLC-based kinase activity assay. The protein 
kinase activity was analyzed using a previously published protocol (with modifications) that 
was reported to quantify Dyrk1a activity in trisomic mouse models [55]. Briefly, protein 
samples (~100 μg) were pre-incubated for 1 minute in a 37°C water bath with a 5-
carboxyfluorescein tagged Woodtide peptide (2 mg/mL) and kinase buffer. ATP (1 mM) was 
added to start the reaction and all samples were incubated in a 37°C water bath for 30 
minutes. Following incubation, the reaction was stopped by the addition of HClO4 (15%) 
and centrifuged at 4 °C for 10 minutes at 14,655 g to remove any sediments. Blanks and the 
samples were placed in conical glass inserts inside 2mL autosampler vials for analysis on 
the Agilent 1260 HPLC. Separation was performed using initial conditions of 85% H2O 
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with 0.1% formic acid (solvent A) and 15% acetonitrile with 0.1% formic acid (solvent B) 
held for 1 minute, followed by a stepwise gradient ending with 5% solvent A and 95% 
solvent B over 11 minutes. FAM-Woodtide fluorescence was measured using a fluorescence 
detector with an excitation wavelength of 485 nm and an emission of 530 nm. The peak 
height and retention time were used to determine the area under the curve for the p-FAM-
Woodtide and FAM-Woodtide. Results were analyzed using OpenLab CDS Chemstation 
software.
2.7 Western Blot to Quantify Dyrk1a Protein
Isolated protein lysates (20μg) from the three brain regions (there was not sufficient femur 
protein to detect Dyrk1a protein) were resolved electrophoretically on polyacrylamide gels 
(Bolt 4–12% Bis Tris Plus Gels), then transferred to PVDF membranes. Membranes were 
blocked in 5% milk in Tris Buffered Saline with 0.1% Tween 20 (TBS-T), incubated 
overnight at 4°C in primary antibodies diluted in 5% milk-TBS-T as follows: rabbit anti-
DYRK1A antibody, 1:500 (A303–802A, Bethyl Laboratories); mouse anti-beta-actin, 
1:5000 (A2228, Sigma Aldrich), and labeled with donkey anti-rabbit IgG AlexaFluor 790 
and donkey anti-mouse IgG AlexaFluor 680 secondary antibodies (1:10,000, Jackson 
Immunoresearch). Fluorescence was detected using a LI-COR CLx Imager. Each membrane 
contained at least three controls (Eu+Water) for a specific brain region (cerebellum, cerebral 
cortex, and hippocampus). Dyrk1a was normalized to actin controls and each normalized 
value was expressed as a ratio relative to the mean of the controls ran that were run within 
each blot. A total of eight independent blots contributed to the final data set.
2.8 Statistical Analyses
For the MCSF, the mean of each of the individual measures (e.g., latency to initial visit, 
duration, frequency, and duration per visit) was generated from the three independent 
observer scores, and scores for each of the five behavioral categories were tabulated as 
shown in Table 1. Five of the Ts65Dn mice with small body size were able to enter into the 
port with the photocell counter and remain there for extended periods of time, so their data 
were excluded from the MCSF analysis (2 Ts+Water; 3 Ts+EGCG). The primary hypothesis 
involved detection of interactive effects of treatment with genotype (i.e., normalization of 
Ts65Dn phenotypes with EGCG), so our approach was to apply parametric ANOVA 
approaches with the emphasis on identifying outcomes showing significant treatment × 
genotype interactions, though all significant ANOVA terms were identified. The total entries 
data (summed across the six included measures) constituted an underlying continuous 
variable and was distributed normally in all but one group (Shapiro-Wilk’s W test), so those 
sums were analyzed directly with a 3-way repeated measures ANOVA with genotype and 
treatment as grouping factors and day as a repeated measure. The other four behavioral 
categories (risk-taking, risk assessment, shelter seeking and exploratory behavior) involved 
measures using different scales (e.g., frequency; duration) and individual measures were 
often not normally distributed. Consequently, the data for each contributing measure (see 
Table 1) were first rank ordered, then the ranks for the measures contributing to a category 
were summed across the measures for each animal to provide a single summed score for the 
animal for each category. To assure that rank ordering reflected increasing amount of the 
target behavior in the category, the subject means of each measure were ranked in ascending 
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order, except for the following which were ranked in descending order a) latency to leave the 
center (long latencies mean assessed risk is low), b) latency to initial slope visit (long 
latencies mean exploratory behavior is low), c) latency to initial hurdle visit (long latencies 
mean exploratory behavior is low), and d) latency to initial DCR visit (long latencies mean 
shelter seeking is low). The summed scores of subject ranks for each of these four categories 
formed a continuous underlying variable for each category and were normally distributed 
within each group in all but two cases (Shapiro-Wilk’s W test), so the data were then 
analyzed with a 3-way mixed measures ANOVA with genotype and treatment as grouping 
factors and day as a repeated measure. In the absence of main or interactive effects of day, 
follow-up analyses of simple main effects of genotype or treatment were performed on the 
data collapsed across day, Fisher’s least significant difference (LSD) tests (α=0.05) were 
used for post hoc comparisons between individual groups to follow up significant ANOVA 
main effects or interactions of genotype and treatment.
The discrimination ratios from the NOR data on the test day, were analyzed with a two-way 
ANOVA using genotype and treatment as a between subjects factor. Fisher’s LSD tests 
(α=0.05) were used for post hoc comparisons between individual groups to follow up 
significant ANOVA main effects or interactions.
For the MWM, the average daily latency and path length over the seven days of training 
were analyzed using a mixed ANOVA with day as a repeated measure and genotype and 
treatment as between-group factors. For each mouse, the daily latency and path length were 
typically strongly correlated across the acquisition period. However, ten of the 70 subjects 
trained in the MWM failed to perform the swimming task well across days (e.g., spending 
>20 sec per trial floating), such that latency and path length were poorly correlated. In those 
cases, (where the correlation was <0.2), the animals were excluded from both acquisition 
and probe MWM analyses (3 Eu+Water, 2 Eu+EGCG, 3 Ts+Water, 3 Ts+EGCG). For the 
probe trial, the time spent in the virtual target disc (in the target quadrant) and the average 
time spent in the 3 equivalent virtual non-target discs (in the other 3 quadrants) were 
analyzed using a mixed ANOVA with treatment group and genotype as between-group 
factors and disc location (target vs non-target) as a repeated measure. For the probe, four of 
the mice that had met the performance criteria during acquisition nevertheless floated for 
>26 seconds during the 60 second probe trial (> 43% of the trial) so they were excluded 
from the probe trial analysis (1 Eu+EGCG, 1 Ts+Water, 2 Ts+EGCG).
The number of paw slips on the balance beam was analyzed using a mixed ANOVA with 
treatment group and genotype as between-group factors, and beam width (12 mm, 9 mm and 
6 mm) as a repeated measure.
For skeletal measurements, many of the measures were not normally distributed and 
transformations were made to achieve normality. Where the transformed measures did not 
achieve normality, non-parametric tests were used. The bone parameters (Tables 3 and 4) 
were analyzed with a two-way ANOVA using genotype and treatment as a between subjects 
variable.
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3. Results
3.1 Growth and EGCG intake
As shown in Table 2, Ts65Dn mice had significantly lower body weights and slower growth 
as compared to euploid mice over days [day × genotype interaction, F(21,1260)=6.96, 
p<0.001]. Both euploid and trisomic mice decreased their daily EGCG consumption (per kg 
body weight) over time [main effect of day, F(15,405)=13.43, p<0.001]; however, there were 
no significant differences in EGCG consumption between the euploid and trisomic mice 
(Table 2).
3.2 MCSF
Total entries—Both euploid and trisomic mice increased the frequency of total entries 
from day 1 to day 2 [main effect of day, F(1,54)=46.36, p<0.001] (see Figure 2), However, 
the trisomic mice showed significantly greater increases in total entries from day 1 to day 2, 
[genotype × day interaction, F(1,59)=7.71, p=0.008]. A two-way ANOVA on total entries 
change scores (day 2-day 1) confirmed the significantly larger increase in the Ts65Dn mice 
[main effect of genotype, F(1, 54)=7.7, p=0.008)]. Follow-up paired sample t-tests 
comparing day 1 and day 2 total scores indicated both Ts65Dn groups significantly 
increased total entries across days whereas for the euploid groups, only the water group 
significantly increased total entries.
Exploratory behavior—There were no significant main or interactive effects found in the 
2-way ANOVA on exploratory behavior (see Supplemental Table 1).
Risk Assessment—The 3-way ANOVA yielded only a main effect of genotype [F(1, 
54)=6.3, p=0.015], with no main or interactive effects of treatment or day, indicating that 
overall the Ts65Dn mice had higher levels of risk assessment across days compared to the 
euploid mice. In the post hoc analysis (as shown in Figure 2b), the increased risk assessment 
of the Ts65Dn mice was mainly due to the significantly higher levels of the Ts65Dn group 
given EGCG compared to either euploid group (p<0.01).
Risk-taking behavior—The 3-way ANOVA yielded a significant genotype × treatment 
interaction [F(1,54)=4.07, p=0.048], with no main or interactive effects of day. As shown in 
Figure 2c, EGCG treatment produced opposite effects in the two genotypes, increasing risk 
taking in euploid mice but decreasing it in Ts65Dn mice.
Shelter Seeking behavior—There were no significant main or interactive effects found 
in the 2-way ANOVA on shelter seeking behavior (see Supplemental Table 1).
There were no significant main or interactive effects found in the 2-way ANOVA on fecal 
counts (see Supplemental Table 4).
3.3 NOR
There were no significant main or interactive effects of genotype or treatment in the 
discrimination ratios for either NOR test.
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3.4 Balance Beam
There were no significant main or interactive effects of genotype or EGCG treatment on the 
balance beam task, though there was a trend for the Ts65Dn-water group to commit more 
paw slips than the euploid-water group. Both groups made more paw slips as the beam width 
decreased [main effect of width, F (2,116) = 100.84, p<0.001] (Supplemental Table 2).
3.5 Morris Water Maze
Across training days, all groups showed significant reductions in path lengths (see Figure 
3a) and latencies to find the platform (Figure 3b) [main effect of day, F(6,276) = 10.2, 
p<0.001 for path length; F(6,276) = 7.32, p=<0.001 for latencies]. The Ts65Dn mice were 
significantly impaired in acquisition relative to control mice, as confirmed by the day × 
genotype interaction both for path length [F(6,276)=2.28, p=0.037] and for latency [F(6,276) 
= 2.2, p=0.041].
There was a main effect of day on swimming speed [F(6,276) =11.98, p<0.001], however 
there were no significant effects of genotype or treatment on swimming speed, indicating 
that the euploid and trisomic groups did not differ on this measure of swimming 
performance. Mice receiving EGCG displayed higher levels of thigmotaxic behavior (Figure 
3c) than those receiving water [main effect of treatment, F(6,276)=2.24, p=0.039], and 
thigmotaxic behavior generally declined over days [main effect of day, F(6,276)=3.65, 
p=0.002], most prominently in the euploid-water group. In addition, trisomic as compared to 
euploid mice displayed significantly less reduction in floating behavior (Figure 3d) over the 
course of acquisition [day × genotype interaction, F(6,276)= 2.64, p=0.017].
For the probe trial (see Figure 4), all groups had a preference for the target quadrant [main 
effect of location (1,42)= 32.84, p= <0.001], and there were no statistically significant main 
or interactive effects of genotype or treatment. A priori paired t-tests comparing time in 
target vs. non-target virtual discs showed that the euploid groups spent significantly more 
time in the target disc (p<0.05), but the differences for the trisomic groups did not reach 
significance. Nevertheless, there were no significant differences in time spent in the target 
quadrant among the four groups. There were no significant main or interactive effects of 
genotype or treatment on the amount of time spent floating, swimming speed, path length or 
the amount of time in thigmotaxis during the probe trial (see Supplemental Table 3).
3.6 Micro CT Analysis of Femora
In the cancellous bone of the distal femoral metaphysis, there were several effects of trisomy 
but no impact of EGCG treatment (Table 3). Bone volume fraction (BV/TV) was 
significantly lower in trisomic as compared to control mice [F(1,43) =6.23, p=0.017]. This 
decrease was likely driven by a significant decrease in trabecular number [F(1,43) =6.23, 
p=0.016] coupled with a significant increase in trabecular separation [F(1,43) =9.07, 
p=0.004] in the trisomic as compared to euploid femora.
For cortical geometry, the Ts65Dn as compared to euploid mice had significantly lower total 
cross sectional area [F(1,42) =9.92, p=0.005], cortical area [F(1,42) =11.99, p=0.001] and 
cortical thickness [F(1,42) =9.00, p=0.005] of the femora. There was also a genotype effect 
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(trisomic mice were significantly decreased compared euploid littermates)in periosteal 
perimeter [F(1,42) =4.74, p=0.035], I-max [F(1,42) =6.05, p=0.018], and I-min [F(1,42) 
=14.51, p<0.001]. Mice that received EGCG had a significantly reduced the cortical area 
[F(1,42) =4.33, p=0.044] and cortical thickness [F(1,42) =5.71, p=0.02].
3.7 Mechanical Testing of Femora
Ts65Dn mice had significantly decreased structural stiffness [F(1,38) =10.17, p=0.003] and 
strength [F(1,38) =10.82, p=0.002] (ultimate force) in the femora as compared to their 
euploid counterparts (Table 4). In addition, yield force was marginally decreased [F(1,38) 
=3.87, p=0.056]. Treatment with EGCG did not produce positive effects on bone mechanics. 
Instead, EGCG’s effects were detrimental at both the structural and tissue levels in both 
trisomic and euploid mice. Structural strength (yield force) [F(1,38) =7.59, p=0.009] and 
ultimate force [F(1,38) =9.83, p=0.033]) were significantly decreased with treatment, 
driving a decrease in work to yield [F(1,38) =4.65, p=0.037]. At the tissue level, ultimate 
stress was significantly decreased [F(1,38) =5.52, p=0.024] and strain to yield was 
marginally decreased [F(1,38) =3.89, p=0.056] in EGCG as compared to water-treated 
bones. There were no effects of trisomy or treatment on any post-yield mechanical 
properties.
3.8 Dyrk1a Protein Levels and Kinase Activity
In protein isolated from the cerebellum, Ts65Dn mice receiving water had significantly 
lower Dyrk1a protein than euploid controls (genotype × treatment interaction [F(1,30)=4.51, 
p=0.043] (see Figure 5). There were no significant effects of genotype or treatment on 
Dyrk1a protein levels in the cerebral cortex, or hippocampus (Table 5).
In protein isolated from femora of Ts65Dn and euploid mice, EGCG treatment significantly 
lowered kinase activity [main effect of treatment, F(1,39)= 6.68, p=0.014] (see Figure 6). 
The trend for an effect of genotype did not reach statistical significance (p=0.064). No 
significant main or interactive effects of genotype or treatment were found in kinase activity 
from protein isolated from cerebral cortex, cerebellum or hippocampus (Table 6).
4. Discussion
The aim of this study was to determine whether oral consumption of EGCG in the drinking 
water that yielded a dosage of ~50 mg/kg/day, higher than the dosage used in our previous 
studies (10–20 mg/kg/day) and comparable to the dosage reported by De la Torre et al. [45], 
would improve cognitive and skeletal phenotypes in the Ts65Dn mouse model of DS. EGCG 
failed to appreciably improve outcomes in trisomic mice in most cognitive/behavioral or 
skeletal measures. One exception to this conclusion was in the MCSF. EGCG significantly 
increased the risk assessment behavior of the Ts65Dn mice relative to both euploid controls 
together with a non-significant increase above Ts65Dn mice given water (which did not 
differ from controls), suggesting that EGCG treatment resulted in more cautious exploration 
of novel environments in the Ts65Dn mice. Consistent with this interpretation, EGCG had 
opposite effects on Ts65Dn and euploid mice on risk taking in the MCSF task, confirmed by 
the significant genotype × treatment interaction, in which EGCG decreased risk taking in 
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Ts65Dn mice but increased risk taking in euploid controls. Although the trisomic mice did 
not have significantly higher risk taking than euploid controls, the interactive effect of 
EGCG on risk taking suggests that EGCG may have some beneficial effects for problem 
behaviors in DS that involve behavioral regulation [60].
No previous studies have been reported assessing the Ts65Dn mouse model using the 
MCSF. The test has been developed as a multidimensional assessment of distinct behavioral 
phenotypes in a complex environment that is rich with alternatives, in which animals are free 
to move around and explore among various compartments and areas [51]. The MCSF can 
enhance sensitivity to treatments such as brain injury or developmental manipulations that 
may produce changes in internal states that may be expressed as differences in behavioral 
patterning or profiles (e.g., in risk taking, risk assessment, shelter seeking, or exploration) 
[52–54, 56]. Our finding that EGCG treatment produces effects in opposite directions for 
risk taking behavior of trisomic and euploid mice raises the intriguing possibility that EGCG 
may improve the maladaptive behavior expressed in risk-related settings [51, 61], and may 
have similar selective effects on adaptive behavioral regulation in unfamiliar environments in 
individuals with DS [49].
As is generally reported, the Ts65Dn mice showed significant impairments in acquisition of 
the MWM, emerging over the first five days (of the seven-day training protocol) and 
accompanied by higher levels of thigmotaxis and floating behavior than the euploid mice 
given water. However, by the last two days there were no significant group differences in 
path length measures. In contrast to most findings (including our previous report [23]), in the 
current study the probe trial (on the 8th day of testing) yielded no significant group 
differences. Since probe trial performance typically reflects the strength of memory for the 
previously learned location, the lack of differences is consistent with all groups reaching 
comparable terminal performance on the last two days of acquisition training. Had the 
groups been given a probe trial test after five days of training (by which time the euploid but 
not the trisomic mice had acquired the spatial learning) rather than after seven training days, 
it is likely that the probe trial would have revealed the trisomic deficit.
The balance beam test did not yield significant deficits in this study, in contrast to the 
impairments reported in our previous study [62]. In the current study, there was a 
nonsignificant trend toward more slips in the Ts65Dn-water group compared to euploid-
water group, but the lack of reliable differences in the balance beam suggests it may be 
susceptible to procedural variability. For example, this study introduced a third, narrower 
beam test that increased difficulty even for the euploid controls and thereby may have 
reduced the overall sensitivity of the task. In addition, we failed to see any significant 
differences between euploid and trisomic mice in the NOR task. This is in agreement with 
our previous finding when mice were given 20mg/kg/day EGCG for approximately 6 weeks 
[23]. While other studies have reported a trisomic deficit in this task, the many 
methodological differences across laboratory settings (types of objects used, light intensity, 
duration of sessions, testing intervals, etc.) may make NOR outcomes perhaps a less reliable 
or generalizable indicator of cognitive deficits.
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The treatment with ~50/mg/kg day EGCG for 7 weeks caused unfavorable effects in bone 
structure and mechanical properties in Ts65Dn and euploid mice, including cortical area, 
cortical thickness, yield force, ultimate force, work to yield, ultimate stress, and strain to 
yield. Ts65Dn mice showed deficits in trabecular bone (percent bone volume, separation and 
number) cortical bone geometry (total cross sectional area, cortical area, cortical thickness, 
periosteal perimeter), I-max, and I-min and bone strength (ultimate force and stiffness), that 
were either not improved or were reduced by EGCG treatment. No post-yield mechanical 
properties were impacted by either trisomy or EGCG treatment. Aside from the change in 
ultimate stress with treatment, all mechanical changes were in whole bone properties which 
suggest that it was mostly changes in bone size/geometry that drove mechanical deficits as 
compared to inferior tissue quality. Similar skeletal deficits including decreases in ultimate 
force and stiffness were quantified in femurs from euploid mice with only one copy of 
Dyrk1a [63].
In contrast, our previous study using a three week administration of EGCG (~10mg/kg/day) 
showed improved skeletal deficits including femoral bone mineral density, percent 
trabecular bone volume, trabecular number and trabecular thickness in Ts65Dn mice [63]. 
These results suggest that in bone, there may be an “inverted U” function of optimal Dyrk1a 
activity, such that an optimal range of activity is necessary to achieve maximum skeletal 
strength, and falling below the threshold (as with high doses of EGCG) or exceeding an 
upper boundary (as with excess activity in trisomy) may be detrimental to bone strength. 
Additionally, when we treated Ts65Dn mice with two EGCG-containing supplements that 
delivered lower daily dosages (3–4 mg/kg/day EGCG), we found that the structure of the 
bone improved but the strength decreased [44]. These data suggested that other catechins or 
a combination of catechins could have a detrimental effect on skeletal strength. Our 
outcomes are among the first to report apparently adverse effects of EGCG treatment in 
association with DS phenotypes in Ts65Dn as well as in normal mice.
This study is one of only a few that has quantified Dyrk1a protein levels and kinase activity 
in brain and/or bone of Ts65Dn mice after undergoing EGCG treatment, and only a few 
studies have examined Dyrk1a protein levels in Ts65Dn mice in specific brain regions. We 
found that trisomic mice displayed decreased Dyrk1a protein levels in the cerebellum, but 
there were no significant effects of trisomy or EGCG treatment on Dyrk1a protein levels in 
the cerebral cortex or the hippocampus. In contrast, Ahmed et al. [64] reported increased 
Dyrk1a protein levels in the hippocampus, cortex and cerebellum of older Ts65Dn mice 
(~5–8 months of age). In addition, increased Dyrk1a protein levels in the hippocampus were 
found in ~3–4 month-old Ts65Dn mice [65]. The discrepancies between these findings and 
those of the current study may reflect differences in age, prior experience (extensive 
behavioral testing in our study) or other methodological differences, and highlight the need 
for a systematic analysis of potential changes in the spatial and temporal expression of 
Dyrk1a protein across the lifespan of Ts65Dn mice.
The relative lack of consistent matches between Dyrk1a brain protein levels and kinase 
activity measures—across trisomic and euploid mice, with and without EGCG treatment— 
suggests that the kinase assay may not be specific for Dyrk1a kinase activity but may be 
indicative of broader kinase activity. We did find a significant EGCG-induced reduction in 
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kinase activity in femur regardless of phenotype, and this effect of EGCG treatment was 
associated with adverse changes in femora cortical structure and overall skeletal strength. 
Taken together, our current results indicate that the reduction in kinase activity in the 
appendicular skeleton after 7 weeks of treatment with ~50 mg/kg/day EGCG was associated 
with detrimental effects on bone structure and strength in trisomic and normal mice, rather 
than the beneficial effects seen with our previous lower-dose treatments. In addition, our 
finding that EGCG did not significantly alter kinase activity in any of the brain regions 
suggests that EGCG treatment either induced compensatory effects on brain Dyrk1a activity 
(or on activity of other kinases that phosphorylate the Woodtide substrate, discussed below) 
or that bioavailability of EGCG was less in brain than in bone.
The kinase activity assay used herein that was modified after Bui et al. [55] has been 
reported to detect Dyrk1a kinase activity levels. The Dyrk1a substrate, 5-
carboxyfluorescein-Woodtide, is derived from amino acids 321–332 of the FOXO1 
transcription factor [66] and was used to determine kinase activity from proteins isolated 
from the cerebral cortex, cerebellum, hippocampus, and femur. One important consideration 
is that in addition to being phosphorylated by Dyrk1a, this protein fragment also is 
phosphorylated by CK1 and may be phosphorylated by other kinases [66]. Although the 
reduction of kinase activity observed in the femur after EGCG treatment may be attributed 
to Dyrk1a inhibition, other kinases that phosphorylate Woodtide may be present and 
inhibited by EGCG. This possibility highlights the need for future studies to identify the 
specific and independent contribution of Dyrk1a phosphorylation of the target peptide.
Our findings highlight important remaining gaps in knowledge about the extent to which 
EGCG holds potential therapeutic value for DS phenotypes and which need to be addressed 
in future studies in mouse models of DS. Preclinical models need to focus on and clarify 
four critical aspects of EGCG treatment: 1) the timing and duration of EGCG 
administration, 2) the optimal dosage of administration, 3) the type of EGCG-containing 
supplement that is administered, and 4) the mechanisms that may account for any 
therapeutic effects of EGCG, including determining whether effects are mediated by 
inhibition of Dyrk1a.
The timing and duration of EGCG administration may determine the effectiveness of the 
treatment. Others have treated with EGCG beginning in adulthood, whereas this and our 
previous studies began treatment in adolescence. When 3-month-old Ts65Dn mice were 
given an EGCG-containing supplement (Life Extension® Mega Green Tea Extract, Lightly 
Caffeinated) in drinking water, improvements in cognitive behaviors was reported [45]. 
Combining treatment with an EGCG-containing supplement and environmental enrichment 
resulted in improvement in hippocampal-dependent MWM task in older 5–6 month-old mice 
[61]. Several studies have assessed EGCG treatment early in development. Treatment with 
pure EGCG during perinatal stages on Ts65Dn mice (25mg/kg via subcutaneous injection 
on PD 3–15) yielded an increase in neurogenesis and related proteins immediately after 
treatment cessation on PD 15, but these cellular effects were transient and were not evident 
at PD 45 and did not significantly improve hippocampal dependent learning and memory in 
trisomic mice [48]. Pregnant Ts65Dn mothers treated with 400mg/kg/day EGCG on 
embryonic days (E) 7 and 8 via oral gavage and saw improvements in the E9.5 1st 
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pharyngeal arch size and cell number and in the size and shape of the cranial vault in 6 week 
old mice [47]. Thus, the age at which the mice are administered an EGCG-containing 
therapeutic appears to be a critical factor in the efficacy of targeted therapeutics. Taken 
together, these data suggest that a pre- or perinatal EGCG treatment, perhaps combined with 
other behaviorally-based therapies during development, may be the most effective 
approaches for EGCG therapeutics for DS phenotypes.
It is essential to identify potential dose-related differences in outcomes with EGCG 
treatment, in part because different doses of EGCG have been hypothesized to affect 
neurocognitive phenotypes differently. For example, it has been reported that a low 
concentration of EGCG produces an anti-apoptotic effect to protect against neurotoxicity 
and a high concentration of EGCG induces a pro apoptotic effect [67]. Our laboratory has 
yet to find significant improvement in cognitive tasks after various doses of pure EGCG 
administration of 3–7 weeks to adolescent Ts65D mice (10, 20, and 50mg/kg/day). A 
perinatal dose of 25mg/kg did not improve hippocampal dependent learning and memory in 
trisomic mice [48]. These findings suggest that varying doses of pure EGCG administered to 
Ts65Dn mice for different periods of time have limited or no effectiveness in improving 
cognitive deficits.
One important consideration is that our studies finding almost no therapeutic benefit used 
pure EGCG, whereas other laboratories that use EGCG-containing supplements that include 
other catechins and unknown components have reported beneficial effects on cognitive 
behavior [45]. This suggests that other molecules found in these supplements may be 
contributing to these reported beneficial effects. We previously used a radioactive-based 
Dyrk1a activity assay (based on activity of antibody-specific isolation of Dyrk1a protein) to 
show that Dyrk1a activity in cerebellum, hippocampus or femur was not significantly 
affected by a three-week adolescent treatment with ~10 mg/kg/day EGCG [23, 26]. In 
contrast, De la Torre and colleagues [45] used a similar radioactivity assay of Dyrk1a kinase 
activity and found significant reductions in Dyrk1a activity in the hippocampus of transgenic 
TgDyrk1a mice (that have an increased copy number of Dyrk1a with no other trisomic 
genes) after treatment for 1 month in adulthood. Calculations of the amount of EGCG 
administered in any dosing regimen must account for the differences in the amount of 
EGCG in the various EGCG-containing supplements used, amount of degradation, and 
should also determine the amount of the other catechins included in those supplements. It 
should be determined whether other catechins (or other molecules) present in the EGCG-
containing supplements could be influencing the observed behavioral improvements. 
Identifying the role of these other catechins in therapeutic outcomes in preclinical mouse 
models will be important to identify the optimal use of supplements as potential therapeutic 
nutraceuticals. This information will allow for better comparisons across studies, and the 
development more targeted therapeutics. Questions also remain about the exact 
bioavailability and blood-brain-barrier penetration of EGCG, given the lack of behavioral 
improvements and failure to inhibit brain kinase activity with pure EGCG administration in 
this study.
Finally, if the therapeutic effects of EGCG are mechanistically caused by inhibition of 
Dyrk1a, then it will be important to demonstrate conclusively that Dyrk1a overexpression 
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and/or increased Dyrk1a activity in specific tissues or specific brain regions can be causally 
linked to specific trisomic phenotypes. The possibility that enduring adverse effects resulting 
from a time- and spatially-limited period of excessive Dyrk1a activity must also be 
considered. We did not detect significant differences in kinase activity between adult euploid 
and Ts65Dn mice in three brain regions. In addition, we did not detect any group differences 
in Dyrk1a protein levels in either the cerebral cortex or hippocampus, and found the 
counterintuitive result that Ts65Dn mice had significantly lower Dyrk1a protein expression 
compared to euploid controls in the cerebellum. If confirmed, this could mean that Dyrk1a 
overexpression/kinase activity is developmentally regulated and its status in adulthood may 
not correlate with or cause observed adult DS phenotypes. It may be that overexpression/
over activity of Dyrk1a at an earlier age or critical period is responsible for these phenotypes 
or that other triplicated genes may be responsible for these deficits. The prospect remains 
that Dyrk1a is a viable target for improving DS phenotypes, but additional information about 
spatiotemporal expression of Dyrk1a and Dyrk1a inhibitors with increased bioavailability 
and well-characterized pharmacological activity in the brain in preclinical studies using 
mouse models of DS must be ascertained.
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Highlights
• EGCG treatment produces minimal improvement in cognitive phenotypes in 
DS mice
• DS mice treated with 50 mg/kg/day EGCG displayed unfavorable bone 
phenotypes
• Dyrk1a protein and kinase activity levels revealed need to understand effects 
of EGCG
• Significant gaps remain regarding potential therapeutic value of EGCG for 
DS traits
Stringer et al. Page 23
Physiol Behav. Author manuscript; available in PMC 2018 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. Behavioral Study Timeline
Timeline for the current study beginning shortly after weaning (PD22). Animals received 
EGCG or water treatment throughout the behavioral testing, even on rest days.
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Figure 2. 
a. MCSF Total Entries. Both Euploid (Eu) and Trisomic (Ts) mice increased the number of 
entries from Day 1 to Day 2. As indicated by (*), Eu+Water, Ts+Water, and Ts+EGCG 
groups had a significantly higher number of total entries on Day 2. Data are represented by 
mean ± SEM.
b. MCSF Risk Assessment Behavior. The Trisomic (Ts) mice exhibited higher risk 
assessment behavior than the Euploid (Eu) mice (data collapsed across both days). As 
indicated by the (*), the Ts+EGCG group displayed significantly higher risk assessment 
behavior compared to both euploid groups. Data are represented by mean ± SEM.
c. MCSF Risk Taking Behavior. There was a significant genotype × treatment interaction. 
Data are collapsed across days since there were no effects of day. Note that EGCG treatment 
had opposing effects on euploid and trisomic mice. Data are represented by mean ± SEM
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Figure 3. 
a. MWM Acquisition Path Length. Acquisition in the Morris water maze spatial learning 
task by the Euploid (Eu) and Trisomic (Ts) groups. Each line represents the average path 
length (meters) for each acquisition day. All groups showed a decrease in latency over 
training days. However, trisomic mice of both treatment groups displayed higher path 
lengths versus the euploid groups (main effect of genotype, indicated by (*). Insert graph 
represents the total path length summed across all 7 acquisition days. Both trisomic groups 
exhibited increased total latency versus euploid-water controls (as indicated by the *). LSD 
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post-hoc analysis revealed a significant increase in Trisomic + Water and Trisomic +EGCG 
latencies as compared to Euploid + Water mice (as indicated by the ×). Data are represented 
as mean ± SEM.
b. MWM Acquisition Latency. Seconds spent locating the hidden platform by the Euploid 
(Eu) and Trisomic (Ts) groups. Each line represents the average time (latency) to find the 
hidden platform for each training day. All groups showed significant reductions in latencies 
over days (main effect of day). However, trisomic mice were significantly impaired versus 
controls (day × genotype interaction, p=0.041). LSD post-hoc analysis revealed a significant 
increase in Trisomic + Water and Trisomic +EGCG latencies as compared to Euploid + 
Water (as indicated by the ×), or increases in Trisomic + EGCG latencies versus Euploid + 
Water mice (as indicated by the +). Data are represented as mean ± SEM.
c. MWM Acquisition Thigmotaxic Behavior. Percent of time spent in thigmotaxis (within 
25.4 cm of the wall) by the Euploid (Eu) and Trisomic (Ts) groups. Each line represents the 
average percent of time for each acquisition day. There was an overall decrease in 
thigmotaxic behavior over training days, most evident in the Euploid-water group; however, 
mice receiving EGCG displayed higher thigmotaxis versus the water groups (main effect of 
treatment, p=0.039), due mainly to the increased thigmotaxic behavior of the Euploid-
EGCG group relative to the euploid-water group. Data are represented as mean ± SEM.
d. MWM Acquisition Floating Behavior. Seconds spent floating by the Euploid (Eu) and 
Trisomic (Ts) groups. Each line represents the average time (seconds) floating for each 
acquisition day. Trisomic mice displayed significantly less reduction in floating behavior 
over days than the euploid mice (day × genotype interaction, p=0.017). Data are represented 
as mean ± SEM.
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Figure 4. MWM Probe Trial
Probe trial performance of Euploid (Eu) and Trisomic (Ts) mice of the two treatment groups 
on the probe trial (Day 8). The (*) comparing the Target and Non-target times of the euploid 
groups indicates a significant spatial bias for the Target location for both euploid groups ; the 
similar trend for the trisomic groups did not reach statistical significance. Bars represent the 
average time spent in the target and non-target quadrant, with error bars represented as SEM.
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Figure 5. Dyrk1a Protein Levels-Cerebellum
Dyrk1a protein levels in the cerebellum of ~9-week old mice given 6 weeks of treatment 
with water or EGCG (mean ± SEM). Ts65Dn mice receiving water had significantly less 
Dyrk1a protein that euploid-water controls (as indicated by the *, genotype × treatment 
interaction, p=0.043).
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Figure 6. Kinase activity-Femur
Kinase activity in the femur of ~9-week old mice given 6 weeks of treatment with water or 
EGCG (mean ± SEM). Mice receiving EGCG treatment had significantly lower kinase 
activity than mice receiving water (main effect of treatment p<0.05).
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Table 2
Average starting weight, final weight and EGCG consumption (corrected for degradation) for the respective 
tested groups.
Group N Body Weight (P24) Body Weight (P68) Average EGCG Consumption (mg/kg/day)
Eu+Water 19 15.9 ± 0.9 28.4 ± 0.6 –
Eu+EGCG 18 15.2 ± 0.9 27.4 ± 0.8 48.7 ± 1.1
Ts+Water 13 12.4 ± 0.3 22.8 ± 0.8 –
Ts+EGCG 15 11.8 ± 0.6 23.9 ± 0.8 52.9 ± 1.4
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Table 3
Skeletal Structure Euploid (n=14) Ts65Dn (n=10) Ts65Dn + EGCG (n=12) Euploid + EGCG (n=11)
Trabecular Bone
Bone mineral density (BMD) (g/cm2)A 0.248 ± 0.009 0.35 ± 0.013 0.222 ± 0.011 0.261 ± 0.010
Percent bone volume (BV/TV) (%)A 30.26 ± 1.38 27.14 ± 2.01 26.10 ± 1.18 30.39 ± 1.34
Trabecular thickness (Tb.Th) (μ) 0.072 ± 0.001 0.072 ± 0.002 0.071 ± 0.001 0.074 ± 0.001
Trabecular separation (Tb.Sp) (mm) A 0.145 ± 0.005 0.166 ± 0.009 0.170 ± 0.007 0.150 ± 0.006
Trabecular number (Tb.N) (1/mm) A 4.204 ± 0.165 3.756 ± 0.220 3.663 ± 0.155 4.103 ± 0.162
Cortical Bone
Total cross sectional area (CSA) (mm2)A 1.73 ± 0.05 1.57 ± 0.06 1.51 ± 0.03 1.66 ± 0.05
Marrow Area (mm2) 0.71 ± 0.03 0.67 ± 0.04 0.67 ± 0.02 0.71 ± 0.03
Cortical Area (mm2)A,B 1.03 ± 0.03 0.90 ± 0.04 0.85 ± 0.02 0.95 ± 0.03
Cortical Thickness (mm)A,B 0.27 ± 0.01 0.25 ± 0.01 0.23 ± 0.01 0.25 ± 0.01
Periosteal BS (mm) 5.63 ± 0.07 5.37 ± 0.10 5.36 ± 0.07 5.46 ± 0.07
Endocortical BS (mm) 3.70 ± 0.07 3.61 ± 0.11 3.63 ± 0.06 3.72 ± 0.06
I max (mm4)A 0.30 ± 0.02 0.24 ± 0.02 0.23 ± 0.01 0.26 ± 0.01
I min (mm4)A 0.14 ± 0.01 0.11 ± 0.01 0.10 ± 0.00 0.13 ± 0.01
Tissue mineral density TMD (g/cmˆ3 HA) 1.21 ± 0.02 1.22 ± 0.02 1.20 ± 0.01 1.21 ± 0.02
A
Main effect of genotype,
B
Main effect of treatment. Parameter values are listed as averages ± (SEM).
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Table 4
Mechanical Testing Euploid (n=13) Ts65Dn (n=9) Ts65Dn + EGCG (n=10) Euploid + EGCG (n=10)
Yield Force (N)B 12.62 ± 0.48 10.40 ± 0.82 9.24 ± 0.72 9.83 ± 0.89
Ultimate Force (N)A,B 18.91 ± 1.14 14.38 ± 1.14 12.19 ± 0.81 14.55 ± 0.90
Displacement to Yield (μm) 136.54 ± 11.22 138.00 ± 6.05 135.40 ± 7.70 115.40 ± 8.57
Postyield Displacement (μm) 688.85 ± 157.27 721.89 ± 234.49 831.80 ± 118.31 838.60 ± 153.17
Total Displacement (μm) 825.38 ± 164.15 859.89 ± 234.20 967.20 ± 121.95 954.00 ± 155.56
Stiffness (N/mm)A 119.04 ± 9.09 92.65 ± 9.08 82.48 ± 5.39 111.42 ± 9.45
Work to Yield (mJ)B 1.01 ± 0.11 0.81 ± 0.08 0.75 ± 0.09 0.68 ± 0.08
Postyield Work (mJ) 8.51 ± 1.11 7.61 ± 2.26 7.35 ± 1.25 8.10 ± 1.49
Total Work (mJ) 9.52 ± 1.12 8.42 ± 2.28 8.09 ± 1.32 8.78 ± 1.53
Yield Stress (MPa) 123.74 ± 6.54 120.06 ± 7.40 119.68 ± 9.43 103.89 ± 9.81
Ultimate Stress (MPa)B 181.31 ± 7.56 165.05 ± 5.64 156.57 ± 8.27 152.12 ± 9.32
Strain to Yield (με)B 12394.20 ± 880.50 12113.17 ± 544.77 11272.60 ± 646.70 10312.85 ± 710.30
Total Strain (με) 74008.75 ± 13842.05 77113.80 ± 22175.14 80917.37 ± 10486.08 85632.10 ± 14167.40
Modulus (GPa) 12.26 ± 0.55 12.03 ± 0.57 12.75 ± 0.73 12.58 ± 0.57
Resilience (MPa) 0.94 ± 0.14 0.83 ± 0.08 0.81 ± 0.10 0.65 ± 0.08
Toughness (MPa) 8.68 ± 1.12 7.98 ± 1.61 8.65 ± 1.35 8.50 ± 1.60
A
Main effect of genotype,
B
Main effect of treatment. Parameter values are listed as averages ± (SEM).
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Table 6
There were no significant effects of genotype or treatment on Dyrk1a activity in the cerebral cortex, 
cerebellum and hippocampus. Data is represented as the area under the curve of the fluorescence emission ± 
SEM.
Cerebral Cortex Cerebellum Hippocampus
Eu+Water (n=8) 143.2 ± 15.0 399.3 ± 21.8 342.6 ± 22.6
Eu+EGCG (n=8) 126.4 ± 14.0 404.9 ± 22.5 290.6 ± 34.6
Ts+Water (n=6) 171.2 ± 18.0 373.8 ± 34.2 287.7 ± 36.8
Ts+EGCG (n=9) 148.8 ± 17.7 424.2 ± 20.7 301.5 ± 21.3
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